Skip to content
    AI Vendor Pulse · Issue 12

    The Front Door of the Trial Goes AI — AI in Site Selection, Feasibility & Study Start-Up

    Open the PDFOpen on LinkedIn

    Sign in to LinkedIn, then select Subscribe.

    Summary

    An executive read on five vendors rebuilding how trials choose and activate sites with AI — Citeline for trial and site intelligence with SmartSolutions and Patient Intelligence, H1 for an investigator data graph moving into site networks and trial execution (Novo Nordisk's StudyHub), Phesi for real-world-data country and site selection, WCG for ClinSphere site enablement and its planned Contract Network acquisition, and ConcertAI for agentic AI (ACT) across feasibility, site selection and activation.

    For market education, not a buying recommendation. The full issue is in the PDF.

    Choosing between vendors like these?

    Vendor advisory looks at workflow fit, vendor evidence, enterprise readiness and regulated-use controls.

    Not sure where to start?

    The AI assessment helps you pick the workflows worth changing first. See selected work for what that looks like.

    The Pulses

    Stay close to what’s changing.

    AI Vendor Pulse and AI Pharma Pulse, published on LinkedIn.

    About 1,070 newsletter subscribers · October 2026

    AI Vendor Pulse

    Mondays

    Open on LinkedIn

    AI Pharma Pulse

    Fridays

    Open on LinkedIn

    To subscribe, sign in to LinkedIn and select Subscribe on the newsletter page.